{"id":"lcp-tacrolimus-qd-mmf-qd-then-mmf-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbances (diarrhea, nausea)"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that blocks IL-2 production and T-cell activation by inhibiting the phosphatase calcineurin. MMF selectively inhibits type II inosine monophosphate dehydrogenase, preferentially affecting T and B lymphocyte proliferation. The combination provides synergistic immunosuppression for transplant rejection prevention, with LCP-tacrolimus offering once-daily dosing convenience compared to immediate-release formulations.","oneSentence":"LCP-tacrolimus is a prolonged-release formulation of tacrolimus that suppresses T-cell activation and proliferation, combined with mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation, together providing dual immunosuppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:44.762Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention (renal, cardiac, hepatic transplantation)"}]},"trialDetails":[{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LCP-tacrolimus QD + MMF QD then MMF QD","genericName":"LCP-tacrolimus QD + MMF QD then MMF QD","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LCP-tacrolimus is a prolonged-release formulation of tacrolimus that suppresses T-cell activation and proliferation, combined with mycophenolate mofetil (MMF) which inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation, together providing dual immunosuppression. Used for Organ transplant rejection prevention (renal, cardiac, hepatic transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}